Prada集团和Bonadonna基金会

Leonardo Brunetti has recently completed his specialization in Medical Oncology. He works at the Fondazione Policlinico Universitario Campus Bio-Medico in Rome and as a clinical researcher in the Phase 1 Unit at Imperial College London. He has long been involved in lung cancer immunotherapy and in the study of biomarkers associated with response and resistance to treatment. For the project he will carry out at the Dana-Farber Cancer Institute in Boston, he will focus on non–small cell lung cancer in order to understand the mechanisms leading to relapse in tumors that initially respond to PD-L1 inhibitors and to identify which antigens evolve in cases of resistance, with the aim of using them as potential therapeutic targets 

Matteo Maria Naldini obtained his MD and a PhD in Molecular Medicine and is currently completing his specialist training in Oncology at the IRCCS San Raffaele Hospital in Milan. The proposed research project, to be conducted at the Cancer Research UK Cambridge Institute of the University of Cambridge, will focus on triple-negative breast cancer and aims to characterize the interactions between tumor and immune cells within the tumor microenvironment, to understand how they influence the response to immunotherapy. To achieve this, he will exploit advanced spatial proteomics technologies, including imaging mass cytometry, to identify and quantify novel clinical response biomarkers useful in guiding therapeutic decisions for precision oncology.